nodes	percent_of_prediction	percent_of_DWPC	metapath
Ivacaftor—P-Glycoprotein Inhibitors—Everolimus—kidney cancer	0.228	0.352	CiPCiCtD
Ivacaftor—Cytochrome P450 3A4 Inhibitors—Everolimus—kidney cancer	0.209	0.324	CiPCiCtD
Ivacaftor—Cytochrome P450 3A4 Inhibitors—Pazopanib—kidney cancer	0.209	0.324	CiPCiCtD
Ivacaftor—ABCB1—kidney cancer	0.097	1	CbGaD
Ivacaftor—ORM1—Erlotinib—kidney cancer	0.0333	0.172	CbGbCtD
Ivacaftor—ABCB1—Temsirolimus—kidney cancer	0.0195	0.101	CbGbCtD
Ivacaftor—CYP3A4—Everolimus—kidney cancer	0.0173	0.0897	CbGbCtD
Ivacaftor—ALB—Erlotinib—kidney cancer	0.014	0.0725	CbGbCtD
Ivacaftor—CYP3A4—Temsirolimus—kidney cancer	0.0117	0.0606	CbGbCtD
Ivacaftor—ABCB1—Pazopanib—kidney cancer	0.0103	0.0531	CbGbCtD
Ivacaftor—ABCB1—Dactinomycin—kidney cancer	0.00939	0.0486	CbGbCtD
Ivacaftor—ABCB1—Gemcitabine—kidney cancer	0.00742	0.0384	CbGbCtD
Ivacaftor—ABCB1—Erlotinib—kidney cancer	0.00733	0.0379	CbGbCtD
Ivacaftor—ABCB1—Paclitaxel—kidney cancer	0.00671	0.0347	CbGbCtD
Ivacaftor—CYP3A4—Pazopanib—kidney cancer	0.00615	0.0318	CbGbCtD
Ivacaftor—ABCB1—Sorafenib—kidney cancer	0.00596	0.0308	CbGbCtD
Ivacaftor—ABCB1—Vinblastine—kidney cancer	0.00588	0.0304	CbGbCtD
Ivacaftor—ABCB1—Vincristine—kidney cancer	0.00578	0.0299	CbGbCtD
Ivacaftor—ABCB1—Sunitinib—kidney cancer	0.00483	0.025	CbGbCtD
Ivacaftor—CYP3A4—Erlotinib—kidney cancer	0.00439	0.0227	CbGbCtD
Ivacaftor—CYP3A4—Paclitaxel—kidney cancer	0.00402	0.0208	CbGbCtD
Ivacaftor—ABCB1—Doxorubicin—kidney cancer	0.00361	0.0187	CbGbCtD
Ivacaftor—CYP3A4—Sorafenib—kidney cancer	0.00357	0.0185	CbGbCtD
Ivacaftor—CYP3A4—Vinblastine—kidney cancer	0.00352	0.0182	CbGbCtD
Ivacaftor—CYP3A4—Vincristine—kidney cancer	0.00347	0.0179	CbGbCtD
Ivacaftor—CYP3A4—Sunitinib—kidney cancer	0.00289	0.015	CbGbCtD
Ivacaftor—CYP3A4—Doxorubicin—kidney cancer	0.00217	0.0112	CbGbCtD
Ivacaftor—Nasopharyngitis—Sunitinib—kidney cancer	0.000221	0.00349	CcSEcCtD
Ivacaftor—Infestation NOS—Erlotinib—kidney cancer	0.00022	0.00348	CcSEcCtD
Ivacaftor—Infestation—Erlotinib—kidney cancer	0.00022	0.00348	CcSEcCtD
Ivacaftor—Aspartate aminotransferase increased—Dactinomycin—kidney cancer	0.000211	0.00333	CcSEcCtD
Ivacaftor—Oropharyngeal pain—Capecitabine—kidney cancer	0.000207	0.00326	CcSEcCtD
Ivacaftor—Rhinitis—Everolimus—kidney cancer	0.000206	0.00324	CcSEcCtD
Ivacaftor—Myalgia—Temsirolimus—kidney cancer	0.000204	0.00322	CcSEcCtD
Ivacaftor—Arthralgia—Temsirolimus—kidney cancer	0.000204	0.00322	CcSEcCtD
Ivacaftor—Unspecified disorder of skin and subcutaneous tissue—Temsirolimus—kidney cancer	0.000203	0.0032	CcSEcCtD
Ivacaftor—Connective tissue disorder—Everolimus—kidney cancer	0.000201	0.00318	CcSEcCtD
Ivacaftor—Transaminases increased—Doxorubicin—kidney cancer	0.000199	0.00314	CcSEcCtD
Ivacaftor—Upper respiratory tract infection—Sunitinib—kidney cancer	0.000199	0.00314	CcSEcCtD
Ivacaftor—Blood bilirubin increased—Capecitabine—kidney cancer	0.000199	0.00313	CcSEcCtD
Ivacaftor—Infestation NOS—Sorafenib—kidney cancer	0.000198	0.00313	CcSEcCtD
Ivacaftor—Infestation—Sorafenib—kidney cancer	0.000198	0.00313	CcSEcCtD
Ivacaftor—Ear pain—Paclitaxel—kidney cancer	0.000195	0.00307	CcSEcCtD
Ivacaftor—Infection—Temsirolimus—kidney cancer	0.000195	0.00307	CcSEcCtD
Ivacaftor—Connective tissue disorder—Erlotinib—kidney cancer	0.000194	0.00307	CcSEcCtD
Ivacaftor—Arthralgia—Pazopanib—kidney cancer	0.000192	0.00304	CcSEcCtD
Ivacaftor—Myalgia—Pazopanib—kidney cancer	0.000192	0.00304	CcSEcCtD
Ivacaftor—Nervous system disorder—Temsirolimus—kidney cancer	0.000192	0.00303	CcSEcCtD
Ivacaftor—Unspecified disorder of skin and subcutaneous tissue—Pazopanib—kidney cancer	0.000191	0.00301	CcSEcCtD
Ivacaftor—Infestation—Sunitinib—kidney cancer	0.000191	0.00301	CcSEcCtD
Ivacaftor—Infestation NOS—Sunitinib—kidney cancer	0.000191	0.00301	CcSEcCtD
Ivacaftor—Skin disorder—Temsirolimus—kidney cancer	0.00019	0.003	CcSEcCtD
Ivacaftor—Aspartate aminotransferase increased—Vincristine—kidney cancer	0.000189	0.00297	CcSEcCtD
Ivacaftor—Mediastinal disorder—Everolimus—kidney cancer	0.000185	0.00291	CcSEcCtD
Ivacaftor—Infection—Pazopanib—kidney cancer	0.000183	0.00289	CcSEcCtD
Ivacaftor—Nasal congestion—Paclitaxel—kidney cancer	0.000183	0.00288	CcSEcCtD
Ivacaftor—Nervous system disorder—Pazopanib—kidney cancer	0.000181	0.00285	CcSEcCtD
Ivacaftor—Skin disorder—Pazopanib—kidney cancer	0.000179	0.00283	CcSEcCtD
Ivacaftor—Aspartate aminotransferase increased—Gemcitabine—kidney cancer	0.000179	0.00282	CcSEcCtD
Ivacaftor—Musculoskeletal discomfort—Temsirolimus—kidney cancer	0.000178	0.00281	CcSEcCtD
Ivacaftor—Mediastinal disorder—Erlotinib—kidney cancer	0.000178	0.00281	CcSEcCtD
Ivacaftor—Connective tissue disorder—Sorafenib—kidney cancer	0.000175	0.00276	CcSEcCtD
Ivacaftor—Hypoglycaemia—Paclitaxel—kidney cancer	0.00017	0.00269	CcSEcCtD
Ivacaftor—Gastrointestinal disorder—Temsirolimus—kidney cancer	0.000169	0.00267	CcSEcCtD
Ivacaftor—Connective tissue disorder—Sunitinib—kidney cancer	0.000168	0.00265	CcSEcCtD
Ivacaftor—Musculoskeletal discomfort—Pazopanib—kidney cancer	0.000168	0.00265	CcSEcCtD
Ivacaftor—Tinnitus—Sorafenib—kidney cancer	0.000166	0.00262	CcSEcCtD
Ivacaftor—Mediastinal disorder—Sorafenib—kidney cancer	0.00016	0.00253	CcSEcCtD
Ivacaftor—Gastrointestinal pain—Temsirolimus—kidney cancer	0.00016	0.00253	CcSEcCtD
Ivacaftor—Ear pain—Capecitabine—kidney cancer	0.00016	0.00252	CcSEcCtD
Ivacaftor—Gastrointestinal disorder—Pazopanib—kidney cancer	0.000159	0.00251	CcSEcCtD
Ivacaftor—Abdominal pain—Temsirolimus—kidney cancer	0.000155	0.00244	CcSEcCtD
Ivacaftor—Hyperaesthesia—Doxorubicin—kidney cancer	0.000154	0.00244	CcSEcCtD
Ivacaftor—Mediastinal disorder—Sunitinib—kidney cancer	0.000154	0.00243	CcSEcCtD
Ivacaftor—Arthralgia—Everolimus—kidney cancer	0.000152	0.0024	CcSEcCtD
Ivacaftor—Myalgia—Everolimus—kidney cancer	0.000152	0.0024	CcSEcCtD
Ivacaftor—Unspecified disorder of skin and subcutaneous tissue—Everolimus—kidney cancer	0.000151	0.00238	CcSEcCtD
Ivacaftor—Gastrointestinal pain—Pazopanib—kidney cancer	0.000151	0.00238	CcSEcCtD
Ivacaftor—Breast disorder—Paclitaxel—kidney cancer	0.00015	0.00237	CcSEcCtD
Ivacaftor—Aspartate aminotransferase increased—Paclitaxel—kidney cancer	0.00015	0.00236	CcSEcCtD
Ivacaftor—Nasopharyngitis—Paclitaxel—kidney cancer	0.000149	0.00235	CcSEcCtD
Ivacaftor—Arthralgia—Erlotinib—kidney cancer	0.000147	0.00231	CcSEcCtD
Ivacaftor—Myalgia—Erlotinib—kidney cancer	0.000147	0.00231	CcSEcCtD
Ivacaftor—Abdominal pain—Pazopanib—kidney cancer	0.000146	0.0023	CcSEcCtD
Ivacaftor—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—kidney cancer	0.000146	0.0023	CcSEcCtD
Ivacaftor—Infection—Everolimus—kidney cancer	0.000145	0.00228	CcSEcCtD
Ivacaftor—Nervous system disorder—Everolimus—kidney cancer	0.000143	0.00225	CcSEcCtD
Ivacaftor—Connective tissue disorder—Vincristine—kidney cancer	0.000142	0.00224	CcSEcCtD
Ivacaftor—Skin disorder—Everolimus—kidney cancer	0.000141	0.00223	CcSEcCtD
Ivacaftor—Infection—Erlotinib—kidney cancer	0.00014	0.0022	CcSEcCtD
Ivacaftor—Nervous system disorder—Erlotinib—kidney cancer	0.000138	0.00217	CcSEcCtD
Ivacaftor—Rhinitis—Gemcitabine—kidney cancer	0.000138	0.00217	CcSEcCtD
Ivacaftor—Skin disorder—Erlotinib—kidney cancer	0.000137	0.00215	CcSEcCtD
Ivacaftor—Connective tissue disorder—Gemcitabine—kidney cancer	0.000135	0.00213	CcSEcCtD
Ivacaftor—Diarrhoea—Temsirolimus—kidney cancer	0.000134	0.00211	CcSEcCtD
Ivacaftor—Upper respiratory tract infection—Paclitaxel—kidney cancer	0.000134	0.00211	CcSEcCtD
Ivacaftor—Musculoskeletal discomfort—Everolimus—kidney cancer	0.000133	0.00209	CcSEcCtD
Ivacaftor—Myalgia—Sorafenib—kidney cancer	0.000132	0.00208	CcSEcCtD
Ivacaftor—Arthralgia—Sorafenib—kidney cancer	0.000132	0.00208	CcSEcCtD
Ivacaftor—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—kidney cancer	0.000131	0.00207	CcSEcCtD
Ivacaftor—Mediastinal disorder—Vincristine—kidney cancer	0.000131	0.00206	CcSEcCtD
Ivacaftor—Dizziness—Temsirolimus—kidney cancer	0.000129	0.00204	CcSEcCtD
Ivacaftor—Infestation NOS—Paclitaxel—kidney cancer	0.000128	0.00202	CcSEcCtD
Ivacaftor—Infestation—Paclitaxel—kidney cancer	0.000128	0.00202	CcSEcCtD
Ivacaftor—Blood bilirubin increased—Doxorubicin—kidney cancer	0.000128	0.00202	CcSEcCtD
Ivacaftor—Musculoskeletal discomfort—Erlotinib—kidney cancer	0.000128	0.00202	CcSEcCtD
Ivacaftor—Myalgia—Sunitinib—kidney cancer	0.000127	0.002	CcSEcCtD
Ivacaftor—Arthralgia—Sunitinib—kidney cancer	0.000127	0.002	CcSEcCtD
Ivacaftor—Diarrhoea—Pazopanib—kidney cancer	0.000126	0.00199	CcSEcCtD
Ivacaftor—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.000126	0.00199	CcSEcCtD
Ivacaftor—Gastrointestinal disorder—Everolimus—kidney cancer	0.000126	0.00198	CcSEcCtD
Ivacaftor—Infection—Sorafenib—kidney cancer	0.000126	0.00198	CcSEcCtD
Ivacaftor—Nervous system disorder—Sorafenib—kidney cancer	0.000124	0.00196	CcSEcCtD
Ivacaftor—Mediastinal disorder—Gemcitabine—kidney cancer	0.000124	0.00195	CcSEcCtD
Ivacaftor—Rash—Temsirolimus—kidney cancer	0.000123	0.00195	CcSEcCtD
Ivacaftor—Dermatitis—Temsirolimus—kidney cancer	0.000123	0.00195	CcSEcCtD
Ivacaftor—Breast disorder—Capecitabine—kidney cancer	0.000123	0.00195	CcSEcCtD
Ivacaftor—Aspartate aminotransferase increased—Capecitabine—kidney cancer	0.000123	0.00194	CcSEcCtD
Ivacaftor—Skin disorder—Sorafenib—kidney cancer	0.000123	0.00194	CcSEcCtD
Ivacaftor—Headache—Temsirolimus—kidney cancer	0.000123	0.00193	CcSEcCtD
Ivacaftor—Nasopharyngitis—Capecitabine—kidney cancer	0.000122	0.00192	CcSEcCtD
Ivacaftor—Dizziness—Pazopanib—kidney cancer	0.000122	0.00192	CcSEcCtD
Ivacaftor—Gastrointestinal disorder—Erlotinib—kidney cancer	0.000121	0.00191	CcSEcCtD
Ivacaftor—Infection—Sunitinib—kidney cancer	0.000121	0.00191	CcSEcCtD
Ivacaftor—Myalgia—Dactinomycin—kidney cancer	0.00012	0.00189	CcSEcCtD
Ivacaftor—Gastrointestinal pain—Vinblastine—kidney cancer	0.00012	0.00189	CcSEcCtD
Ivacaftor—Nervous system disorder—Sunitinib—kidney cancer	0.000119	0.00188	CcSEcCtD
Ivacaftor—Gastrointestinal pain—Everolimus—kidney cancer	0.000119	0.00188	CcSEcCtD
Ivacaftor—Skin disorder—Sunitinib—kidney cancer	0.000118	0.00186	CcSEcCtD
Ivacaftor—Rash—Pazopanib—kidney cancer	0.000116	0.00183	CcSEcCtD
Ivacaftor—Nausea—Temsirolimus—kidney cancer	0.000116	0.00183	CcSEcCtD
Ivacaftor—Dermatitis—Pazopanib—kidney cancer	0.000116	0.00183	CcSEcCtD
Ivacaftor—Abdominal pain—Vinblastine—kidney cancer	0.000116	0.00182	CcSEcCtD
Ivacaftor—Headache—Pazopanib—kidney cancer	0.000116	0.00182	CcSEcCtD
Ivacaftor—Rhinitis—Paclitaxel—kidney cancer	0.000115	0.00182	CcSEcCtD
Ivacaftor—Musculoskeletal discomfort—Sorafenib—kidney cancer	0.000115	0.00182	CcSEcCtD
Ivacaftor—Abdominal pain—Everolimus—kidney cancer	0.000115	0.00182	CcSEcCtD
Ivacaftor—Gastrointestinal pain—Erlotinib—kidney cancer	0.000115	0.00181	CcSEcCtD
Ivacaftor—Infection—Dactinomycin—kidney cancer	0.000114	0.0018	CcSEcCtD
Ivacaftor—Connective tissue disorder—Paclitaxel—kidney cancer	0.000113	0.00178	CcSEcCtD
Ivacaftor—Abdominal pain—Erlotinib—kidney cancer	0.000111	0.00175	CcSEcCtD
Ivacaftor—Musculoskeletal discomfort—Sunitinib—kidney cancer	0.000111	0.00175	CcSEcCtD
Ivacaftor—Upper respiratory tract infection—Capecitabine—kidney cancer	0.00011	0.00173	CcSEcCtD
Ivacaftor—Nausea—Pazopanib—kidney cancer	0.00011	0.00173	CcSEcCtD
Ivacaftor—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000109	0.00172	CcSEcCtD
Ivacaftor—Myalgia—Vincristine—kidney cancer	0.000107	0.00169	CcSEcCtD
Ivacaftor—Tinnitus—Paclitaxel—kidney cancer	0.000107	0.00169	CcSEcCtD
Ivacaftor—Infestation NOS—Capecitabine—kidney cancer	0.000105	0.00166	CcSEcCtD
Ivacaftor—Infestation—Capecitabine—kidney cancer	0.000105	0.00166	CcSEcCtD
Ivacaftor—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000105	0.00166	CcSEcCtD
Ivacaftor—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.000105	0.00166	CcSEcCtD
Ivacaftor—Mediastinal disorder—Paclitaxel—kidney cancer	0.000104	0.00164	CcSEcCtD
Ivacaftor—Gastrointestinal pain—Sorafenib—kidney cancer	0.000103	0.00163	CcSEcCtD
Ivacaftor—Infection—Vincristine—kidney cancer	0.000102	0.00161	CcSEcCtD
Ivacaftor—Arthralgia—Gemcitabine—kidney cancer	0.000102	0.00161	CcSEcCtD
Ivacaftor—Myalgia—Gemcitabine—kidney cancer	0.000102	0.00161	CcSEcCtD
Ivacaftor—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000101	0.0016	CcSEcCtD
Ivacaftor—Nervous system disorder—Vincristine—kidney cancer	0.000101	0.00159	CcSEcCtD
Ivacaftor—Diarrhoea—Vinblastine—kidney cancer	0.0001	0.00158	CcSEcCtD
Ivacaftor—Abdominal pain—Sorafenib—kidney cancer	0.0001	0.00158	CcSEcCtD
Ivacaftor—Diarrhoea—Everolimus—kidney cancer	9.97e-05	0.00157	CcSEcCtD
Ivacaftor—Gastrointestinal pain—Sunitinib—kidney cancer	9.95e-05	0.00157	CcSEcCtD
Ivacaftor—Infection—Gemcitabine—kidney cancer	9.7e-05	0.00153	CcSEcCtD
Ivacaftor—Dizziness—Vinblastine—kidney cancer	9.67e-05	0.00153	CcSEcCtD
Ivacaftor—Dizziness—Everolimus—kidney cancer	9.63e-05	0.00152	CcSEcCtD
Ivacaftor—Abdominal pain—Sunitinib—kidney cancer	9.62e-05	0.00152	CcSEcCtD
Ivacaftor—Diarrhoea—Erlotinib—kidney cancer	9.62e-05	0.00152	CcSEcCtD
Ivacaftor—Nervous system disorder—Gemcitabine—kidney cancer	9.57e-05	0.00151	CcSEcCtD
Ivacaftor—Skin disorder—Gemcitabine—kidney cancer	9.48e-05	0.0015	CcSEcCtD
Ivacaftor—Rhinitis—Capecitabine—kidney cancer	9.47e-05	0.00149	CcSEcCtD
Ivacaftor—Gastrointestinal pain—Dactinomycin—kidney cancer	9.42e-05	0.00149	CcSEcCtD
Ivacaftor—Musculoskeletal discomfort—Vincristine—kidney cancer	9.38e-05	0.00148	CcSEcCtD
Ivacaftor—Dizziness—Erlotinib—kidney cancer	9.29e-05	0.00147	CcSEcCtD
Ivacaftor—Connective tissue disorder—Capecitabine—kidney cancer	9.28e-05	0.00146	CcSEcCtD
Ivacaftor—Rash—Everolimus—kidney cancer	9.18e-05	0.00145	CcSEcCtD
Ivacaftor—Dermatitis—Everolimus—kidney cancer	9.18e-05	0.00145	CcSEcCtD
Ivacaftor—Headache—Vinblastine—kidney cancer	9.16e-05	0.00144	CcSEcCtD
Ivacaftor—Headache—Everolimus—kidney cancer	9.13e-05	0.00144	CcSEcCtD
Ivacaftor—Abdominal pain—Dactinomycin—kidney cancer	9.11e-05	0.00144	CcSEcCtD
Ivacaftor—Hypoglycaemia—Doxorubicin—kidney cancer	9.01e-05	0.00142	CcSEcCtD
Ivacaftor—Musculoskeletal discomfort—Gemcitabine—kidney cancer	8.89e-05	0.0014	CcSEcCtD
Ivacaftor—Gastrointestinal disorder—Vincristine—kidney cancer	8.88e-05	0.0014	CcSEcCtD
Ivacaftor—Rash—Erlotinib—kidney cancer	8.86e-05	0.0014	CcSEcCtD
Ivacaftor—Dermatitis—Erlotinib—kidney cancer	8.85e-05	0.0014	CcSEcCtD
Ivacaftor—Headache—Erlotinib—kidney cancer	8.8e-05	0.00139	CcSEcCtD
Ivacaftor—Tinnitus—Capecitabine—kidney cancer	8.8e-05	0.00139	CcSEcCtD
Ivacaftor—Nausea—Vinblastine—kidney cancer	8.69e-05	0.00137	CcSEcCtD
Ivacaftor—Nausea—Everolimus—kidney cancer	8.65e-05	0.00136	CcSEcCtD
Ivacaftor—Diarrhoea—Sorafenib—kidney cancer	8.65e-05	0.00136	CcSEcCtD
Ivacaftor—Arthralgia—Paclitaxel—kidney cancer	8.53e-05	0.00134	CcSEcCtD
Ivacaftor—Myalgia—Paclitaxel—kidney cancer	8.53e-05	0.00134	CcSEcCtD
Ivacaftor—Mediastinal disorder—Capecitabine—kidney cancer	8.51e-05	0.00134	CcSEcCtD
Ivacaftor—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	8.47e-05	0.00134	CcSEcCtD
Ivacaftor—Gastrointestinal disorder—Gemcitabine—kidney cancer	8.43e-05	0.00133	CcSEcCtD
Ivacaftor—Gastrointestinal pain—Vincristine—kidney cancer	8.42e-05	0.00133	CcSEcCtD
Ivacaftor—Dizziness—Sorafenib—kidney cancer	8.36e-05	0.00132	CcSEcCtD
Ivacaftor—Nausea—Erlotinib—kidney cancer	8.35e-05	0.00132	CcSEcCtD
Ivacaftor—Diarrhoea—Sunitinib—kidney cancer	8.32e-05	0.00131	CcSEcCtD
Ivacaftor—Abdominal pain—Vincristine—kidney cancer	8.14e-05	0.00128	CcSEcCtD
Ivacaftor—Infection—Paclitaxel—kidney cancer	8.12e-05	0.00128	CcSEcCtD
Ivacaftor—Dizziness—Sunitinib—kidney cancer	8.05e-05	0.00127	CcSEcCtD
Ivacaftor—Nervous system disorder—Paclitaxel—kidney cancer	8.02e-05	0.00126	CcSEcCtD
Ivacaftor—Rash—Sorafenib—kidney cancer	7.97e-05	0.00126	CcSEcCtD
Ivacaftor—Dermatitis—Sorafenib—kidney cancer	7.97e-05	0.00126	CcSEcCtD
Ivacaftor—Breast disorder—Doxorubicin—kidney cancer	7.95e-05	0.00125	CcSEcCtD
Ivacaftor—Skin disorder—Paclitaxel—kidney cancer	7.94e-05	0.00125	CcSEcCtD
Ivacaftor—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	7.92e-05	0.00125	CcSEcCtD
Ivacaftor—Headache—Sorafenib—kidney cancer	7.92e-05	0.00125	CcSEcCtD
Ivacaftor—Diarrhoea—Dactinomycin—kidney cancer	7.88e-05	0.00124	CcSEcCtD
Ivacaftor—Nasopharyngitis—Doxorubicin—kidney cancer	7.87e-05	0.00124	CcSEcCtD
Ivacaftor—Rash—Sunitinib—kidney cancer	7.67e-05	0.00121	CcSEcCtD
Ivacaftor—Dermatitis—Sunitinib—kidney cancer	7.66e-05	0.00121	CcSEcCtD
Ivacaftor—Headache—Sunitinib—kidney cancer	7.62e-05	0.0012	CcSEcCtD
Ivacaftor—Nausea—Sorafenib—kidney cancer	7.51e-05	0.00118	CcSEcCtD
Ivacaftor—Musculoskeletal discomfort—Paclitaxel—kidney cancer	7.45e-05	0.00117	CcSEcCtD
Ivacaftor—Rash—Dactinomycin—kidney cancer	7.26e-05	0.00115	CcSEcCtD
Ivacaftor—Nausea—Sunitinib—kidney cancer	7.23e-05	0.00114	CcSEcCtD
Ivacaftor—Upper respiratory tract infection—Doxorubicin—kidney cancer	7.07e-05	0.00111	CcSEcCtD
Ivacaftor—Gastrointestinal disorder—Paclitaxel—kidney cancer	7.06e-05	0.00111	CcSEcCtD
Ivacaftor—Diarrhoea—Vincristine—kidney cancer	7.04e-05	0.00111	CcSEcCtD
Ivacaftor—Arthralgia—Capecitabine—kidney cancer	7e-05	0.0011	CcSEcCtD
Ivacaftor—Myalgia—Capecitabine—kidney cancer	7e-05	0.0011	CcSEcCtD
Ivacaftor—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	6.95e-05	0.0011	CcSEcCtD
Ivacaftor—Nausea—Dactinomycin—kidney cancer	6.84e-05	0.00108	CcSEcCtD
Ivacaftor—Dizziness—Vincristine—kidney cancer	6.81e-05	0.00107	CcSEcCtD
Ivacaftor—Infestation NOS—Doxorubicin—kidney cancer	6.78e-05	0.00107	CcSEcCtD
Ivacaftor—Infestation—Doxorubicin—kidney cancer	6.78e-05	0.00107	CcSEcCtD
Ivacaftor—Gastrointestinal pain—Paclitaxel—kidney cancer	6.68e-05	0.00105	CcSEcCtD
Ivacaftor—Diarrhoea—Gemcitabine—kidney cancer	6.68e-05	0.00105	CcSEcCtD
Ivacaftor—Infection—Capecitabine—kidney cancer	6.66e-05	0.00105	CcSEcCtD
Ivacaftor—Nervous system disorder—Capecitabine—kidney cancer	6.58e-05	0.00104	CcSEcCtD
Ivacaftor—Skin disorder—Capecitabine—kidney cancer	6.52e-05	0.00103	CcSEcCtD
Ivacaftor—Rash—Vincristine—kidney cancer	6.49e-05	0.00102	CcSEcCtD
Ivacaftor—Dermatitis—Vincristine—kidney cancer	6.48e-05	0.00102	CcSEcCtD
Ivacaftor—Abdominal pain—Paclitaxel—kidney cancer	6.46e-05	0.00102	CcSEcCtD
Ivacaftor—Headache—Vincristine—kidney cancer	6.45e-05	0.00102	CcSEcCtD
Ivacaftor—Rash—Gemcitabine—kidney cancer	6.16e-05	0.000971	CcSEcCtD
Ivacaftor—Dermatitis—Gemcitabine—kidney cancer	6.15e-05	0.00097	CcSEcCtD
Ivacaftor—Headache—Gemcitabine—kidney cancer	6.12e-05	0.000965	CcSEcCtD
Ivacaftor—Nausea—Vincristine—kidney cancer	6.11e-05	0.000964	CcSEcCtD
Ivacaftor—Musculoskeletal discomfort—Capecitabine—kidney cancer	6.11e-05	0.000964	CcSEcCtD
Ivacaftor—Rhinitis—Doxorubicin—kidney cancer	6.1e-05	0.000962	CcSEcCtD
Ivacaftor—Connective tissue disorder—Doxorubicin—kidney cancer	5.98e-05	0.000943	CcSEcCtD
Ivacaftor—Nausea—Gemcitabine—kidney cancer	5.8e-05	0.000915	CcSEcCtD
Ivacaftor—Gastrointestinal disorder—Capecitabine—kidney cancer	5.79e-05	0.000913	CcSEcCtD
Ivacaftor—Tinnitus—Doxorubicin—kidney cancer	5.67e-05	0.000895	CcSEcCtD
Ivacaftor—Diarrhoea—Paclitaxel—kidney cancer	5.59e-05	0.000882	CcSEcCtD
Ivacaftor—Gastrointestinal pain—Capecitabine—kidney cancer	5.48e-05	0.000865	CcSEcCtD
Ivacaftor—Mediastinal disorder—Doxorubicin—kidney cancer	5.48e-05	0.000865	CcSEcCtD
Ivacaftor—Dizziness—Paclitaxel—kidney cancer	5.41e-05	0.000852	CcSEcCtD
Ivacaftor—Abdominal pain—Capecitabine—kidney cancer	5.3e-05	0.000836	CcSEcCtD
Ivacaftor—Rash—Paclitaxel—kidney cancer	5.15e-05	0.000813	CcSEcCtD
Ivacaftor—Dermatitis—Paclitaxel—kidney cancer	5.15e-05	0.000812	CcSEcCtD
Ivacaftor—Headache—Paclitaxel—kidney cancer	5.12e-05	0.000808	CcSEcCtD
Ivacaftor—Nausea—Paclitaxel—kidney cancer	4.86e-05	0.000766	CcSEcCtD
Ivacaftor—Diarrhoea—Capecitabine—kidney cancer	4.59e-05	0.000724	CcSEcCtD
Ivacaftor—Myalgia—Doxorubicin—kidney cancer	4.51e-05	0.000711	CcSEcCtD
Ivacaftor—Arthralgia—Doxorubicin—kidney cancer	4.51e-05	0.000711	CcSEcCtD
Ivacaftor—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	4.48e-05	0.000706	CcSEcCtD
Ivacaftor—Dizziness—Capecitabine—kidney cancer	4.44e-05	0.0007	CcSEcCtD
Ivacaftor—Infection—Doxorubicin—kidney cancer	4.3e-05	0.000677	CcSEcCtD
Ivacaftor—Nervous system disorder—Doxorubicin—kidney cancer	4.24e-05	0.000669	CcSEcCtD
Ivacaftor—Rash—Capecitabine—kidney cancer	4.23e-05	0.000667	CcSEcCtD
Ivacaftor—Dermatitis—Capecitabine—kidney cancer	4.23e-05	0.000666	CcSEcCtD
Ivacaftor—Headache—Capecitabine—kidney cancer	4.2e-05	0.000663	CcSEcCtD
Ivacaftor—Skin disorder—Doxorubicin—kidney cancer	4.2e-05	0.000662	CcSEcCtD
Ivacaftor—Nausea—Capecitabine—kidney cancer	3.98e-05	0.000628	CcSEcCtD
Ivacaftor—Musculoskeletal discomfort—Doxorubicin—kidney cancer	3.94e-05	0.000621	CcSEcCtD
Ivacaftor—Gastrointestinal disorder—Doxorubicin—kidney cancer	3.73e-05	0.000589	CcSEcCtD
Ivacaftor—Gastrointestinal pain—Doxorubicin—kidney cancer	3.54e-05	0.000558	CcSEcCtD
Ivacaftor—Abdominal pain—Doxorubicin—kidney cancer	3.42e-05	0.000539	CcSEcCtD
Ivacaftor—Diarrhoea—Doxorubicin—kidney cancer	2.96e-05	0.000467	CcSEcCtD
Ivacaftor—Dizziness—Doxorubicin—kidney cancer	2.86e-05	0.000451	CcSEcCtD
Ivacaftor—Rash—Doxorubicin—kidney cancer	2.73e-05	0.00043	CcSEcCtD
Ivacaftor—Dermatitis—Doxorubicin—kidney cancer	2.72e-05	0.00043	CcSEcCtD
Ivacaftor—Headache—Doxorubicin—kidney cancer	2.71e-05	0.000427	CcSEcCtD
Ivacaftor—Nausea—Doxorubicin—kidney cancer	2.57e-05	0.000405	CcSEcCtD
